Navigation Links
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008

ALIMTA Lung Cancer Study Highlighting Key Histology Findings to Be Included

in May 15 ASCO Live, Online Presscast

INDIANAPOLIS, May 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from more than 50 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from May 30 to June 3, 2008. The company will present the latest research findings on ALIMTA(R) (pemetrexed for injection), GEMZAR(R) (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's leadership in thoracic cancer research.

Of note is a pivotal Phase III study (ASCO Abstract # 8011) that demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in ASCO's live online presscast. The virtual press event will be the first time ASCO has selected researchers to present key abstracts prior to its annual meeting.

"Improved patient outcomes via tailored therapy continues to be our focus and this year's ASCO is no exception," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "With Lilly studies focusing on thoracic and breast cancer, among others, this meeting will continue to show our commitment to answering the unmet needs of cancer care."

Key Pemetrexed Abstracts for ASCO 2008:

-- Abstract # 8011: June 2, 2008; 3:00 p.m.

-- Maintenance pemetrexed plus best supportive care (BSC) versus

placebo plus BSC: A phase III study

-- This study will be featured during ASCO presscast on May 15

-- Abstract # 8096: June 1, 2008; 2:00 p.m.

-- Comparison of patient outcomes stratified by histology among

pemetrexed-treated patients with stage IIIB/IV NSCLC in two Phase

II trials

-- Abstract # 8097: June 1, 2008; 2:00 p.m.

-- Resource utilization by non-small cell lung cancer histology:

Results from the randomized, phase III trial of

pemetrexed/cisplatin versus gemcitabine/cisplatin

For more information on Lilly Oncology agents, including full prescribing information, please visit .

(Logo: )

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lilly Declares Second-Quarter Dividend
2. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
3. Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement
4. Lilly Sets Date and Conference Call for First Quarter 2008 Financial Results Announcement
5. State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
6. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
7. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
8. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
9. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
10. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
11. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: ) , ... ,world firsts,: , TwinLink™ - the first ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: